Background {#Sec1}
==========

Juvenile dermatomyositis (JDM) is a rare autoimmune disease characterized by proximal muscle weakness concurrent with specific cutaneous manifestations. \[[@CR1]\] In the United States, JDM has an estimated incidence of 2--4 per million children per year. \[[@CR2]\] While improved management of the disease has led to reduced mortality in recent years, up to 40% JDM patients continue to have active disease despite treatment. \[[@CR3], [@CR4]\] Ongoing disease activity, cumulative damage, and aggressive immunosuppressive treatments remain a concern for long term outcomes and quality of life. \[[@CR4]\] Previous studies have compared cost of specific JDM treatment regimens \[[@CR5]\], evaluated the inpatient burden of adult dermatomyositis \[[@CR6]\], and examined economic burden of other childhood inflammatory conditions such as JIA \[[@CR7]\]. However, little is known about the inpatient burden of JDM in the United States. As a result, use of a comprehensive, national inpatient database could help to elucidate the economic burden posed by JDM.

Previous studies found racial/ethnic and socioeconomic differences in hospitalization rates and outcomes for stroke \[[@CR8]\], cardiovascular disease \[[@CR9]\], asthma \[[@CR10]\], acute respiratory illness \[[@CR11]\], pemphigus \[[@CR12]\], and adult dermatomyositis \[[@CR6]\]. We hypothesized that JDM is also associated with similar racial/ethnic and socioeconomic differences, possibly related to lack of insurance coverage and reduced access to specialty care, such as rheumatology and dermatology. In the present study, we analyzed the prevalence and predictors of hospitalization, cost of care and length of stay in US patients with JDM.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The 2002--2012 Nationwide Inpatient Sample (NIS) provided by the Healthcare Cost and Utilization Project (HCUP) from the Agency for Healthcare Research and Quality (AHRQ) was analyzed. Each year of NIS contains an approximately 20% stratified representative sample of all inpatient hospitalizations in the United States. Sample weights were created by NIS that factored the sampling design of hospitals in the US. These sample weights are needed to provide representative estimates of hospital discharges across the whole country. All data were de-identified and no attempts were made to identify any of the individuals in the database. All parties with access to the HCUP were compliant to HCUP's formal data use agreement. This study was deemed exempt by the institutional review board at Northwestern University.

Identification of JDM {#Sec4}
---------------------

The databases were searched for a primary and/or secondary diagnosis of JDM using the International Classification of Diseases, Ninth Revision, Clinical Modification (*ICD-9-CM)* code 710.3. The primary diagnosis was defined in NIS as the condition chiefly responsible for admission to the hospital for care. A previous study validated the use of the discharge diagnosis code 710.3 in the inpatient setting for the study of dermatomyositis. \[[@CR13]\] Patients with *ICD-9-CM* diagnostic codes of 701.0/710.1 (scleroderma), 710.0 (systemic lupus erythematosus), 710.4 (polymyositis), 710.8 (mixed connective tissue disease), and 710.9 (undifferentiated connective tissue disease) were excluded to minimize misclassification. The control group included all hospitalizations without any diagnosis of JDM, yielding a representative cohort of US pediatric hospitalizations.

Data processing and statistics {#Sec5}
------------------------------

All data analyses and statistical processes were performed using SAS version 9.4 (SAS Institute, Cary, NC). Analyses of survey responses were performed using SURVEY procedures. Weighted prevalence (95% confidence intervals \[CI\]) of hospitalization either with a primary or secondary *ICD-9-CM* code of JDM were determined. The hospital cost for inpatient care was calculated based on the total charge of the hospitalization and the cost-to-charge ratio estimated by HCUP. All costs were adjusted for inflation to the year 2014 according to the Consumer Price Index from the United States Bureau of Labor Statistics. \[[@CR14]\] Summary statistics were generated for length of stay (LOS), inflation-adjusted cost-of-care, including sum, mean and 95% confidence interval (CI) for hospitalizations with a primary, secondary or no diagnosis of JDM.

Three different regression models were constructed. \[[@CR1]\] Survey logistic regression models were used to determine the predictors of hospitalization for JDM. The dependent variable was hospitalization with a primary diagnosis of JDM vs. no JDM. Linear regression models with log-transformed \[[@CR2]\] cost of care or \[[@CR3]\] length of stay (LOS) as the dependent variables were used to determine the predictors of cost of hospitalization and length of stay LOS. Cost of care and LOS were log-transformed because they were not normally distributed. The independent variable was a primary diagnosis of JDM vs. no JDM. Other independent variables included age (0--5, 6--11, 11--17), season of admission (fall, winter, spring, summer), sex (male, female), race/ethnicity (White, Black, Hispanic, Other\[Asian, Native American, and other racial/ethnic groups\]), health insurance coverage (Medicaid, private, self-pay, no charge/charity, non-Medicaid government administered insurance programs \[e.g. KidCare, Children's Health Insurance Program (CHIP), other federal/state/local government\]) number of comorbid chronic conditions (0--1, 2--5, ≥6), hospital location (metropolitan \[≥1 urban cluster of population ≥ 50,000\] \>1million, fringe/metro \< 1 million, micropolitan \[≥1 urban cluster of population 10,000-49,999\], not metropolitan or micropolitan), hospital region (Northeast, Midwest, South and West), and an indicator for calendar year (2002--2003, 2004--2005, 2006--2007, 2008--2009, 2010--2011, 2012). Chronic conditions were defined by HCUP as lasting ≥12 months and meeting one or both of the following: (a) places limitations on self-care, independent living, and social interactions (b) results in the need for ongoing intervention with medical products, services, and special equipment. \[[@CR15]\] Chronic condition count was calculated and provided by HCUP. Crude odds ratios (OR), beta-coefficients and 95% CI were estimated. Multivariate regression models were constructed using stepwise selection (alpha = 0.1) from the abovementioned covariates. Adjusted OR, beta coefficients and 95% CI were estimated. All statistical models included discharge trend weights, sample strata that account for hospital's census region or division, ownership/control, location/teaching and bedsize that were provided by NIS and clustering by individual hospital. Complete case-analysis was performed. A two-sided *P*-value \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Juvenile dermatomyositis patient and hospital characteristics {#Sec7}
-------------------------------------------------------------

Overall, there were 14,401,668 pediatric discharges captured in the NIS between the years 2002--2012. 4,879,511 pediatric discharges remained after exclusion of live births and other connective tissue diseases. There were 909 and 495 admissions with a primary or secondary diagnosis of JDM (weighted frequencies of 4317 and 2321, respectively). The weighted prevalences of primary and secondary hospitalization for JDM ranged from 144.0--228.8 and 71.9--133.8 per million patients per year (Fig. [1](#Fig1){ref-type="fig"}). Hospitalization rates for patients with a primary or secondary diagnosis of JDM did not significantly increase after 2003 compared with years 2002--2003 (generalized linear models, *P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Annual prevalence of hospitalizations for patients with primary/secondary diagnoses of juvenile dermatomyositis (JDM). Survey weighted logistic regression was performed to compare the prevalence of hospitalization for JDM over time. Hospitalization rates for patients with a primary or secondary diagnosis of JDM did not significantly increase after 2003 compared with years 2002--2003 (generalized linear models, *P* \< 0.05)

Pediatric patients with a primary or secondary diagnosis of JDM were significantly older than those without such a diagnosis (mean \[standard deviation\] age, 8.77 \[0.25\] and 10.23 \[0.30\] vs. 6.19\[0.05\] years). Hospitalizations with a primary diagnosis of JDM were associated with older patient age compared to hospitalizations without a primary diagnosis of JDM (survey logistic regression; OR \[95% CI\]) (6--11: 5.79 \[4.23--7.93\]; 11--17: 2.57 \[1.87--3.51\]) (Table [1](#Tab1){ref-type="table"}). Patients who were admitted for a primary diagnosis of JDM were more likely to be female (2.17 \[1.74--2.71\]), receive financial coverage from non-Medicaid government administered insurance programs (2.59 \[2.26--2.97\]) compared to private insurance, and have multiple chronic conditions (2--5: 1.89 \[1.45--2.45\]), but were less likely to have Medicaid (0.66 \[0.54--0.81\]) compared to private insurance. Primary admissions for JDM were less likely to occur in hospitals in nonmetropolitan areas (fringe area or metropolitan area with \< 1 million people: 0.65 \[0.43--0.99\]; micropolitan: 0.30 \[0.15--0.57\]; not metropolitan or micropolitan: 0.24 \[0.13--0.45\]) and more likely to occur during the summer (1.44 \[1.15--1.80\]).Table 1Associations of hospitalization for JDM in US childrenVariablePrimary diagnosis of JDMNoYesFreqRow Percent\
\[95% CI\]FreqPercent\
\[95% CI\]Crude OR\
\[95% CI\]*P*Adjusted OR\
\[95% CI\]*P*Age 0--512,470,78355.00 \[54.35--55.64\]107725.18 \[19.85--30.52\]Reference--Reference-- 6--113,371,27214.87 \[14.65--15.09\]168639.42 \[33.59--45.25\]5.79 \[4.23--7.93\]\<.00014.62 \[4.18--5.10\]\<.0001 11--176,832,98330.13 \[29.47--30.80\]151435.39 \[29.87--40.91\]2.565 \[1.872--3.514\]\<.00011.86 \[1.67--2.06\]\<.0001Season Fall5,305,48525.01 \[24.89--25.14\]95825.29 \[21.95--28.64\]1.21 \[0.97--1.52\]0.09801.18 \[1.06--1.33\]0.004 Winter6,135,92628.93 \[28.69--29.17\]91624.18 \[20.81--27.54\]Reference--Reference-- Spring5,007,15423.61 \[23.51--23.71\]89223.53 \[20.49--26.57\]1.19 \[0.97--1.46\]0.09311.13 \[1.01--1.27\]0.0349 Summer4,761,75522.45 \[22.29--22.61\]102327.00 \[23.73--30.27\]1.44 \[1.15--1.80\]0.00151.53 \[1.37--1.71\]\<.0001Gender Female10,343,98854.16 \[54.03--54.30\]275364.74 \[59.70--69.70\]2.170 \[1.739--2.708\]\<.00012.22 \[2.05--2.42\]\<.0001 Male12,222,93945.84 \[45.70--45.97\]149935.26 \[30.21--40.30\]Reference--Reference--Race White9,127,70751.60 \[49.63--53.57\]171251.83 \[43.21--60.45\]Reference--Reference-- Black2,970,64716.79 \[15.48--18.11\]52916.02 \[11.32--20.71\]0.949 \[0.650--1.388\]0.78890.83 \[0.73--0.94\]0.0026 Hispanic3,975,46524.47 \[20.45--24.50\]81124.56 \[17.39--31.72\]1.088 \[0.731--1.619\]0.67811.01 \[0.91--1.13\]0.8044 Other1,615,4169.13 \[8.24--10.03\]2517.60 \[3.71--11.48\]0.828 \[0.462--1.485\]0.52710.60 \[0.51--0.71\]\<.0001Insurance Medicaid10,669,49346.42 \[45.17--47.66\]153035.47 \[30.99--39.95\]0.658 \[0.538--0.805\]\<.00010.71 \[0.65--0.78\]\<.0001 Private insurance10,435,36445.40 \[44.06--46.74\]227352.71 \[47.02--58.40\]Reference--Reference-- Self-pay855,1643.72 \[3.28--4.16\]1052.44 \[0.21--4.66\]0.564 \[0.226--1.408\]0.21970.57 \[0.43--0.76\]\<.0001 No charge43,3300.19 \[0.12--0.26\]90.20 \[0.00--0.48\]0.903 \[0.226--3.606\]0.88501.91 \[0.97--3.76\]0.0595 Non-Medicaid government program888,1903.86 \[3.53--4.20\]3969.18 \[5.08--13.29\]2.047 \[1.253--3.344\]0.00432.59 \[2.26--2.97\]\<.0001Number of Chronic Conditions 0--116,472,39771.53 \[70.36--72.70\]247957.42 \[50.81--64.03\]Reference--Reference-- 2 to 55,928,33625.74 \[24.77--26.72\]168238.96 \[33.40--44.52\]1.885 \[1.451--2.449\]\<.00011.41 \[1.30--1.54\]\<.0001 6+627,8352.73 \[2.48--2.97\]1563.62 \[1.47--5.76\]1.653 \[0.844--3.236\]0.14261.24 \[1.00--1.52\]0.046Hospital Location Metropolitan \>1million7,153,68037.36 \[33.68--41.04\]19,30051.32 \[40.24--62.41\]Reference--Reference-- Fringe/Metro \< 1 million9,216,26748.13 \[44.80--51.47\]162443.19 \[32.59--53.79\]0.653 \[0.431--0.989\]0.04430.70 \[0.64--0.77\]\<.0001 Micropolitan1,736,3509.07 \[8.20--9.94\]1393.69 \[1.48--5.91\]0.296 \[0.154--0.572\]0.00030.27 \[0.21--0.35\]\<.0001 Not metropolitan or micropolitan1,041,0385.44 \[4.92--5.95\]671.79 \[0.73--2.86\]0.240 \[0.127--0.454\]\<.00010.25 \[0.18--0.34\]\<.0001Region Northeast4,281,72018.59 \[15.96--21.23\]81418.87 \[7.69--30.04\]Reference--Reference-- Midwest4,853,59321.08 \[17.99--24.16\]88320.45 \[10.90--29.99\]0.956 \[0.463--1.976\]0.90350.82 \[0.71--0.94\]0.0047 South8,992,20439.05 \[35.41--42.69\]145033.59 \[21.57--45.61\]0.848 \[0.421--1.708\]0.64410.83 \[0.74--0.94\]0.0020 West4,901,05121.28 \[18.32--24.25\]117027.10 \[15.36--38.84\]1.255 \[0.599--2.632\]0.54701.23 \[1.11--1.36\]\<.0001Missing data was encountered in 74,174 (1.7%) for age, 400,342(10.5%) for season, 96,625 (2.3%) for sex, 1,120,507 (26.2%) for race, 8898, (0.2%) for insurance, 0 (0.0%) for number of chronic conditions, 830,247 (19.7%) for hospital location, and 0 (0.0%) for regionThere was no significant differences of missing values for season (*p* = 0.37), race/ethnicity (*p* = 0.76), or hospital location (*p* = 0.14) between hospitalizations with a primary, secondary, or no diagnosis of JDM. 95% *CI* 95% confidence interval; *OR* odds ratio

In multivariate logistic regression models with stepwise selection, non-white race, Medicaid insurance, self-pay, non-metropolitan area, and Midwest and South regions were all associated with lower rates of admission for JDM patients compared to those without a primary diagnosis of JDM, whereas older age, female sex, non-Medicaid government administered insurance coverage, multiple chronic conditions, non-winter seasons and West region were all associated with higher rates of admission for JDM compared to those without a primary diagnosis of JDM (Table [1](#Tab1){ref-type="table"}).

Reasons for secondary admission {#Sec8}
-------------------------------

The top 3 primary admission diagnoses for patients with a secondary diagnosis of JDM were: cellulitis of leg (rank, prevalence \[95% CI\]) (\#1, 4.38% \[3.46--5.30\]), cellulitis of arm (\#2, 4.22% \[3.31--5.12\]), and pneumonia (\#3, 3.66% \[2.81--4.51\]). Meanwhile, the top 3 primary admission diagnoses for inpatients without a diagnosis of JDM were: pneumonia (\#1, 5.24% \[5.23--5.25\]), acute bronchiolitis due to RSV (\#2, 3.34% \[3.33--3.35\], and asthma with exacerbation (\#3, 3.04% \[3.03--3.05\]) (Table [2](#Tab2){ref-type="table"}).Table 2Top five primary diagnoses of patients admitted with secondary or no diagnosis of JDMRankICD-9-CM CodePrimary diagnosisWeighted FrequencyPrevalence\
\[95% CI\]Secondary diagnosis of JDM 16826Cellulitis of Leg101.620644.38%\[3.46--5.30\] 26823Cellulitis of Arm97.864534.22%\[3.31--5.12\] 3486Pneumonia84.989563.66%\[2.81--4.51\] 4V5789Rehabilitation procedure NEC84.560493.64%\[2.77--4.51\] 588Other arthropod-borne disease52.252672.25%\[1.58--2.93\]No diagnosis of dermatomyositis 1486Pneumonia1,206,3175.24%\[5.23--5.25\] 246,611Acute Bronchiolitis Due to RSV768,6373.34%\[3.33--3.35\] 349,392Asthma, unspecified, with exacerbation700,1803.04%\[3.03--3.05\] 446,619Acute Bronchiolitis Due to Other Infectious Organism561,4432.44%\[2.43--2.45\] 55409Acute appendicitis w/o mention of peritonitis550,9232.39%\[2.39--2.40\]ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification; 95% CI 95% confidence interval; RSV respiratory syncytial virus; NEC Not Elsewhere Classifiable

The frequency of diagnosis codes for the most common symptoms in JDM as documented in other studies \[[@CR16], [@CR17]\] was also analyzed (Table [3](#Tab3){ref-type="table"}). Compared to non-JDM patients, ten of the most common symptoms (rash, muscle weakness, muscle pain, fever, dysphagia, abdominal pain, arthritis, calcinosis, melena, and anorexia) were more frequent in JDM patients. However, the prevalence of *ICD-9-CM* codes for these symptoms within the dataset was lower than documented prevalence of these symptoms within other published studies \[[@CR16], [@CR17]\].Table 3Primary or Secondary Diagnoses of Most Common Symptoms in Patients with Secondary and No diagnosis of JDM from 2002 to 2012Rank*ICD-9-CM* Code^a^DiagnosisWeighted\
FrequencyRow Prevalence \[95% CI\]710.3 as Secondary Diagnosis 1782.1Rash441.87 \[0.65--3.10\] 2728.87Muscle Weakness401.72 \[0.39--3.05\] 3729.1Muscle Pain301.30 \[0.33--2.28\] 4780.6Fever964.14 \[2.26--6.01\] 5787.20Dysphagia451.94 \[0.43--3.46\] 6784.42Dysphonia0-- 7789.00Abdominal Pain230.97 \[0.11--1.83\] 8CCS 204Arthritis NOS803.44 \[1.86--5.02\] 9709.3Calcinosis271.14 \[0.06--2.23\] 10578.1Melena80.36 \[0.00--0.86\] 11783.0Anorexia100.43 \[0.00--1.04\]No Diagnosis of 710.3 1782.1Rash166,9320.73 \[0.68--0.77\] 2728.87Muscle Weakness81520.04 \[0.03--0.04\] 3729.1Muscle Pain31,8790.14 \[0.13--0.15\] 4780.6Fever621,4632.70 \[2.53--2.87\] 5787.20Dysphagia64,2400.28 \[0.23--0.32\] 6784.42Dysphonia18360.01 \[0.00--0.01\] 7789.00Abdominal Pain159,3170.69 \[0.65--0.73\] 8CCS 204Arthritis NOS136,9580.59 \[0.56--0.63\] 9709.3Calcinosis10250.0044 \[0.0036--0.0053\] 10578.1Melena59,5090.26 \[0.24--0.28\] 11783.0Anorexia67,5010.29 \[0.25--0.33\]^a^Excluded repeat diagnosis of JDMICD9-CM International Classification of Diseases, Ninth Revision, Clinical Modification; 95% CI 95% confidence interval; NOS Not Otherwise Specified

Length of stay {#Sec9}
--------------

Patients with JDM spent a weighted total of 19,159 days and 18,218 days in the hospital for their JDM or other reasons, respectively. LOS in the hospital was 39% longer for hospitalizations with a secondary diagnosis (geometric mean \[95% CI\]: 3.75 \[3.27--4.30\] days) (*p* \< 0.0001) compared with hospitalizations without a diagnosis of JDM while hospitalizations were not prolonged for a primary diagnosis (2.50 \[2.27--2.76\]) when compared with hospitalizations without a diagnosis of JDM (2.70 \[2.66--2.75\]). This pattern of prolonged LOS for hospitalizations with a secondary diagnosis of JDM was consistent across all years (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Length of stay and costs of hospitalization with primary/secondary diagnoses for juvenile dermatomyositis (JDM). (**a**) Total and (**b**) geometric mean length of hospital stay and (**c**) total and (**d**) geometric mean inflation-adjusted cost of inpatient care are presented for 2002--2003, 2004--2005, 2006--2007, 2008--2009, 2010--2011 and 2012. *jdm* 0: no JDM. *jdm* 1: primary dx of JDM. *jdm* 2: secondary dx of JDM

In multivariate weighted linear regression models of log-transformed LOS, increased LOS in patients with a primary diagnosis of JDM was associated with race/ethnicity (beta coefficient \[95% CI\]) (Hispanic: 0.28 \[0.14--0.41\]; Other: 0.59 \[0.31--0.86\]), type of insurance (Medicaid: 0.16 \[0.01--0.31\]), multiple chronic conditions (2--5: 0.41 \[0.29--0.52\]; 6+: 0.94 \[0.63--1.26\]), micropolitan location (0.59 \[0.27--0.90\]), and South region (0.34 \[0.12--0.56\]) (Table [4](#Tab4){ref-type="table"}). Note that since LOS was log transformed, coefficients from regression models of log-transformed LOS are not the same scale as raw LOS.Table 4Predictors of Length of Stay and Cost of Care for Hospitalizations with a Primary Diagnosis of JDM-Length of StayCost of CareLSMAdj Beta \[95% CI\]^a^*p*-valueLSMAdj Beta \[95% CI\]\**p*-valueAge 0--51.720 \[ref\]--9.470 \[ref\]-- 6--101.51−0.22\[− 0.34\--0.09\]0.0019.43− 0.03\[− 0.24--0.17\]0.7459 11--171.69− 0.04\[− 0.19--0.12\]0.64179.640.18\[− 0.07--0.42\]0.1536Season Fall1.62−0.05\[− 0.16--0.06\]0.34429.570.00\[− 0.24--0.23\]0.9674 Winter1.670 \[ref\]--9.570 \[ref\]-- Spring1.6−0.07\[− 0.15--0.01\]0.08539.45− 0.13\[− 0.35--0.09\]0.2514 Summer1.66− 0.01\[− 0.11--0.08\]0.75529.46− 0.11\[− 0.33--0.10\]0.3131Gender Female1.640.01\[− 0.09--0.11\]0.89929.540.05\[− 0.13--0.23\]0.5914 Male1.630 \[ref\]--9.490 \[ref\]--Race White1.380 \[ref\]--9.320 \[ref\]-- Black1.550.17\[− 0.12--0.46\]0.23959.440.12\[− 0.21--0.45\]0.4806 Hispanic1.660.28 \[0.14--0.41\]\<.00019.620.30 \[0.05--0.55\]0.0168 Other1.960.59 \[0.31--0.86\]\<.00019.680.36\[−0.07--0.79\]0.0993Insurance Medicaid1.620.16 \[0.01--0.31\]0.03869.320.02\[−0.21--0.25\]0.8646 Private insurance1.460 \[ref\]--9.30 \[ref\]-- Self-pay1.70.24\[−0.07--0.55\]0.13169.520.22\[−0.67--1.10\]0.6276 No charge2.110.65\[−0.06--1.37\]0.073910.481.18\[−0.56--2.93\]0.1833 Non-Medicaid government program1.3−0.16\[− 0.29\--0.04\]0.00858.95−0.34\[− 0.63\--0.06\]0.0196Number of Chronic Conditions 0--11.190 \[ref\]--9.060 \[ref\]-- 2 to 51.590.41 \[0.29--0.52\]\<.00019.420.36 \[0.17--0.55\]0.0002 6+2.130.94 \[0.63--1.26\]\<.000110.071.01 \[0.39--1.63\]0.0014Hospital Location Metropolitan \>1million1.460 \[ref\]--9.520 \[ref\]-- Fringe/Metro \< 1 million1.41−0.04\[−0.14--0.05\]0.37049.35−0.17\[− 0.36--0.02\]0.0835 Micropolitan2.040.59 \[0.27--0.90\]0.00039.870.35\[−0.20--0.91\]0.2128 Not metropolitan or micropolitan1.640.19\[−0.69--1.07\]0.67539.31−0.20\[− 0.98--0.58\]0.6082Region Northeast1.620 \[ref\]--9.350 \[ref\]-- Midwest1.51−0.10\[−0.29--0.09\]0.2859.630.28\[−0.04--0.59\]0.0875 South1.950.34 \[0.12--0.56\]0.00249.630.28 \[0.00--0.56\]0.0529 West1.47−0.15\[−0.35--0.05\]0.13429.440.09\[−0.17--0.35\]0.5113Year 2002--20031.790 \[ref\]--9.550 \[ref\]-- 2004--20051.64−0.15\[−0.31--0.02\]0.07859.44−0.11\[− 0.44--0.23\]0.5253 2006--20071.53−0.26\[− 0.47\--0.05\]0.01469.34− 0.21\[− 0.57--0.15\]0.2445 2008--20091.73−0.06\[− 0.24--0.11\]0.47599.610.06\[− 0.29--0.40\]0.7548 2010--20111.51− 0.18\[− 0.49--0.14\]0.26669.39−0.16\[− 0.52--0.20\]0.3796 20121.61−0.28\[− 0.43\--0.13\]0.00039.750.20\[− 0.14--0.54\]0.2469Missing data was encountered in 74,174 (1.7%) for age, 400,342(10.5%) for season, 96,625 (2.3%) for sex, 1,120,507 (26.2%) for race, 8898, (0.2%) for insurance, 0 (0.0%) for number of chronic conditions, 830,247 (19.7%) for hospital location, 0 (0.0%) for region, and 0 (0.0%) for yearThere were no significant differences of missing values for season (*p* = 0.37), race/ethnicity (*p* = 0.76), or hospital location (*p* = 0.14) between hospitalizations with a primary, secondary, or no diagnosis of JDM. LSM least squares mean; 95% *CI* 95% confidence interval^a^Coefficients from regression models of log-transformed LOS or cost of care should be interpreted with caution as the transformed variables are not the same scale as the raw variables

Cost of care {#Sec10}
------------

The weighted total inflation-adjusted cost-of-care for patients with a primary and secondary inpatient diagnosis of JDM was \$49,339,995 and \$49,784,853 respectively. The actual total cost is likely higher as 106 patients had a missing value for charge and cost. The inflation-adjusted cost of care for hospitalization was 64% higher for hospitalizations with a primary diagnosis (geometric mean \[95% CI\]: \$7350 \[\$6228--\$8674\] and 64% higher for a secondary diagnosis (\$7352 \[\$6331--\$8537\]) of JDM than those with no diagnosis of JDM (4479 \[\$4295--\$4671\] (*p* \< 0.0001 for both). This pattern of higher costs for hospitalizations for JDM was consistent for every year within the cohort.

In multivariate linear regression models of log-transformed cost of care, increased cost-of-care in patients with a primary diagnosis of JDM was associated with race/ethnicity (beta coefficient \[95% CI\] Hispanic: 0.30 \[0.05--0.55\]) and multiple chronic conditions (2--5: 0.36 \[0.17--0.55\]; 6+: 1.01 \[0.39--1.63\]).

Discussion {#Sec11}
==========

The present study finds that JDM incurs a significant inpatient burden, with primary diagnoses having a higher cost of care (approximately \$3000 more per hospitalization) and secondary diagnoses having longer hospitalizations and cost of care (also approximately \$3000 more per hospitalization) compared to no diagnosis of JDM. The higher cost of care is likely related to additional workup required for diagnosis, disease comorbidity and treatment regimen required for the disease. Previous studies have suggested that infection may play a role in both the development \[[@CR18]\] and recurrence \[[@CR19], [@CR20]\] of JDM episodes. In our study, we found increased rates of infection i.e. cellulitis among JDM patients. Multiple mechanisms may make individuals with JDM more prone to infection with pathogens such as staphylococcus. Skin breakdown, seen in JDM patients with calcinosis and cutaneous ulceration, may serve as a nidus for infection. In addition, underlying immune dysregulation such as granulocyte chemotactic defects may contribute to infection risk. \[[@CR21]\] The long-term use of immunosuppressants (e.g. corticosteroids, methotrexate) likely also contributes to infection risk. A novel finding that 'other arthropod-borne diseases' represented the 5th most common primary diagnosis among patients with a secondary diagnosis of JDM (Table [2](#Tab2){ref-type="table"}) deserves further study to determine the strength of this association, whether the code refers specifically to arthropod-borne diseases per se versus chief complaints (e.g. cutaneous eruptions, other infections) for which arthropod-borne diseases are on the differential diagnosis, or an outlier due to readmission of a few inpatients with JDM who happened to have had arthropod-borne diseases. JDM patients within our study were also shown to have higher rates of comorbid chronic conditions. Emerging literature supports the finding that JDM patients are often medically complex. For example, we recently found in a separate study that inpatients with JDM had increased odds of multiple cardiovascular and cerebrovascular comorbidities. \[[@CR22]\] It is likely that sequelae of JDM itself, adverse effects of treatment (e.g. infections, side effects of steroids), and concomitant autoimmunity contribute to higher chronic condition counts in JDM, with further study needed to better clarify the exact comorbidities in this population. In addition, while current treatment regimens favoring rapid and aggressive management, such as those involving high-dose intravenous pulse methylprednisone therapy, improve outcomes and prognosis of the disease \[[@CR23]\], they may also contribute to inpatient costs. Unfortunately, we did not have access to specific diagnostic tests and medications used during hospitalizations, as these were not recorded within the NIS. As a result, future studies are needed to determine specific contributors to inpatient costs. Notably, annual prevalence for both primary and secondary diagnoses have not increased over time as opposed to trends seen in adult dermatomyositis. \[[@CR6]\] Future studies are needed to assess whether disease pathophysiology or management may explain the differences in these trends.

There were significant age, sex, seasonal, financial, and regional differences in hospitalization for JDM. In particular, higher rates of hospitalization were found in JDM patients who were older, female, received non-Medicaid government administered insurance coverage (e.g. KidCare, CHIP, other federal/state/local government programs), hospitalized in metropolitan areas, and hospitalized in non-winter seasons when compared to the control group. Hospitalization rates were highest for the 6--11 year old age group, which corresponds to the average age of onset (approximately 7 years) found in other studies. \[[@CR18], [@CR24]\] Higher rates of hospitalization in females are likely related to females having higher overall disease prevalence. \[[@CR2], [@CR18]\] Hospitalizations for JDM were more likely to occur in non-winter seasons, which stand in stark contrast to the higher frequency of winter admissions seen in control patients. This finding reinforces that ultraviolet light and other environmental exposures may play a role in disease pathogenesis and exacerbation, which corroborates the view that JDM can be a photosensitive condition \[[@CR25]--[@CR27]\] and that JDM patients should be advised to routinely use sunscreen. \[[@CR28]\]

Financial coverage and regional differences in hospitalizations may point to differences in access to care for different patient populations. Notably, patients were more likely to be hospitalized if they were covered under government programs, excluding Medicaid. These alternative programs often represent efforts at the state/local level to provide assistance for children of lower income families. As a result, increased risk of hospitalization for patients with these alternative forms of coverage may represent the decreased access to care that lower income families face. Paradoxically, hospitalizations rates were lower among JDM patients with Medicaid coverage. As a result, further research is needed to evaluate how differences in group characteristics and social determinants of health between those covered under different government programs may contribute to differences in outcomes as seen in this study. Additionally, the majority of hospitalizations occurred in metropolitan locations. This speaks to multiple potential issues, including access to outpatient care in urban settings and lack of pediatric rheumatologists in more rural settings requiring treatment at large referral centers in urban areas, both of which may be attributable to a limited supply of pediatric rheumatologists \[[@CR29]\] and pediatric subspecialists in general. \[[@CR30]\] This is further reinforced by the fact that hospitalizations for JDM in micropolitan locations resulted in an 80% longer LOS compared to metropolitan locations. Further research is needed to evaluate how distribution and access to the pediatric rheumatology workforce affects patient outcomes.

Interestingly, race/ethnicity did not play a major role in increased hospitalizations, contrasting trends seen across other diseases, including adult dermatomyositis \[[@CR6]\], pemphigus \[[@CR12]\], and psoriasis \[[@CR31]\] where racial/ethnic differences did affect rates of hospitalization. However, race was an important contributor to inpatient burden in terms of both length of stay and cost, with Hispanic patients having an estimated 32% longer hospitalization and 35% higher cost of care and other non-white racial groups (excluding Black and Hispanic patients) having 80% longer hospitalizations. These differences in length of stay and costs of care may point to differences in disease manifestations or severity among different races/ethnicities. Indeed, previous studies have found differences in human leukocyte antigen (HLA) frequencies among different ethnic groups, with the HLA-DQA1\*0501 allele having a high frequency in Hispanic JDM patients. \[[@CR32]\] In addition, studies have suggested that differences between patient HLA subtype and autoantibody associations may help predict disease subtype and severity. \[[@CR33]\] Alternatively, access to care may be contributing to racial/ethnic differences. However, one study, which found that minority race and lower family income were associated with worse outcomes---as measured by Childhood Health Assessment Questionnaire, patient global scores, and health-related quality of life scores---did not find associations between race and proxy measures of access to care e.g. time to diagnosis, disease duration, and treatment. \[[@CR34]\] In our own study, we did not find that Black patients experienced a difference in hospitalization, length of stay, or cost of care, although we did find that these outcomes differed among other minority groups. Further research examining the relationship of race/ethnicity to outcomes in JDM are warranted.

Strengths of this study include an analysis of a nationally representative sample of all payer data over a period of 11 years with over 14 million pediatric records. JDM patients were identified using the previously validated *ICD-9-CM* codes for dermatomyositis in the inpatient setting. \[[@CR13]\] Limitations of this study include the inability to distinguish between different degrees of disease severity or specific clinical features. This limited our ability to examine how differences between individual hospitals and patient characteristics might contribute to LOS and cost of care. Due to the structure of the NIS dataset, it was not possible to determine how many of the hospitalizations were due to readmissions or transfers between hospitals. In addition, cost analysis did not include costs of physician services, out-of-pocket expenses or outpatient costs. Thus the total economic burden of JDM is likely much higher. In addition, while common symptoms for JDM were higher among the JDM cohort, little additional insight could be gleaned due to lack of symptom coding within the database, as prevalence of these codes was much lower than documented prevalence of these symptoms. \[[@CR16], [@CR17]\] There was a large frequency of missing data for season, race/ethnicity, and hospital location in NIS. However, there were no significant differences of missing values between hospitalizations with a primary, secondary or no diagnosis of dermatomyositis. Finally, geographic variation was considered by four Health Resources and Services Administration regions. Controlling for region did not attenuate the observed seasonal, racial/ethnic, or hospital location differences. However, future studies using more granular distinctions of geographic location would be useful to further validate these seasonal, racial, and hospital location differences.

Conclusions {#Sec12}
===========

The findings of this study indicate that the inpatient burden of JDM is extensive. Cost was higher for patients with primary JDM while both length of stay and cost were higher for secondary dermatomyositis versus those without. Older age, female sex, non-winter season, non-Medicaid administered government insurance coverage, and metropolitan area were associated with higher rates of hospitalization for JDM while race/ethnicity was more influential in resulting in increased LOS and cost of care, particularly in Hispanic populations. Future research is needed to identify how factors such as access to care may relate to the financial, regional, and racial differences found within this study.
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